A weekly doctor-insider briefing on the five signals that matter in clinical trials: one global standards shift, one FDA update, one EMA update, one safety signal, and one event or industry move.
Written and curated by Daria Morozova, MD, a clinical trial project manager with a background in hematology and experience in international multicentre studies.
Bringing a medical and operational perspective to the developments shaping clinical research.
Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated. Demo entries are for layout testing only and should not be treated as verified reporting.
This week: Kenya confirming the first imported Bundibugyo Ebola case as DRC cases pass 8,600, FDA setting out how it would design the first ibogaine trials, EMA making its pre-submission advice for EU clinical trial applications permanent, FDA telling a court its mifepristone safety review will finish in March, and argenx stopping its Phase 3 Sjögren's trial for futility.
This week: a US indictment over counterfeit Ozempic sourced from China and sold into American distribution, FDA launching a nationwide drive to fill advisory committee seats, EMA's Board told the Biotech Act will touch about 70% of CTIS, the MHRA flagging laboratory assay interference and a fatal parenteral nutrition embolism, and the first US approval for MCT8 deficiency.
This week: the Ervebo trial against Bundibugyo Ebola starting in Ituri, FDA commissioner nominee Heidi Overton backing advisory committees and career-staff product decisions at her hearing, EMA piloting a new pre-submission model for marketing applications, FDA replacing 'animal tests' with 'nonclinical tests' across its drug regulations, and the draft biosimilar user fee deal proposing a provisional approval pathway.
This week: the UK suspending avacopan for new patients, leaving the product's status split three ways across major regulators, FDA's centre directors warning that foreign trial data they cannot verify may be excluded, PRAC opening an EU-wide review of injectable iron days after FDA's Injectafer boxed warning, Novartis and BMS pausing autoimmune CAR-T trials after serious inflammatory events, and remibrutinib beating teriflunomide in two Phase 3 MS trials.
This week: individualised mRNA cancer vaccines posting a Phase 3 win and a Phase 2 survival imbalance nine days apart, FDA extending the deramiocel review after a post-advisory-committee data package, the four-week countdown to CTIS's new annual safety report module, a new FDA clinical hold on RGX-121 after spinal MRI findings, and CARDIO-TTRansform's full results at ESC confirming the topline miss.
This week: the MHRA publishing its route to 14-day reviews for low-risk Phase 1 trials, the White House nominating Heidi Overton as FDA commissioner after three months of acting leadership, the EU approving teclistamab plus daratumumab from second-line myeloma, Ervebo doses being released for use outside the Bundibugyo trial as well as inside it, and an independent data monitoring committee ending AstraZeneca's eVOLVE-Lung02 for futility.
This week: WHO moving to a randomised Phase 3 trial of Ervebo against Bundibugyo Ebola as the outbreak passed 4,600 confirmed cases, FDA granting the first myeloma accelerated approval based on MRD negativity, EMA opening its reliance pilot for post-authorisation changes to more companies, new immune globulin lots withdrawn for hypersensitivity reactions, and Jazz agreeing to buy Actio Biosciences for up to $1.32 billion.
This week: FDA licensing the first mRNA influenza vaccine six months after refusing to review it, FDA granting accelerated approval to RP1 after two rejections and over its own review team's recommendation, the European Commission formally revoking Tavneos over pivotal trial data handling, the MHRA reminding patients and prescribers that common medicines change how the body copes with heat, and Curium agreeing to buy Lantheus for up to $8 billion.
This week: Health Canada setting trial registration and results-disclosure expectations and launching a new public trial portal, FDA finalising three guidances to broaden cancer trial eligibility, the EU authorising XFG-adapted COVID-19 vaccines within a week of CHMP's opinion, the MHRA adding an overlap syndrome warning to checkpoint inhibitors, and two back-to-back FDA advisory committees showing how statistical analysis plan changes can decide an application.
This week: WHO consulting on its first full rewrite of the 1995 GCP guideline, aligned with ICH E6(R3), FDA approving GSK's zidesamtinib two months early on a single-arm trial, CHMP recommending twelve new medicines including the first oral IL-23 receptor blocker, an FDA advisory committee overriding agency staff to back compounding of unapproved peptides, and Repligen buying the company whose cell-therapy preservation media sit inside many of today's trials.
This week: EBO-PEP launching the first trial of post-exposure prophylaxis against Bundibugyo Ebola, FDA finalising its psychedelic trial guidance three years after the draft, EMA publishing ICH E6(R3) Annex 2 with a 15 January 2027 effective date, EU and UK healthcare professionals receiving new avacopan safety letters, and AstraZeneca licensing a China-discovered lung cancer drug for up to $1.5 billion.
This week: the largest ATTR-CM outcomes trial to date missing its primary endpoint when an RNA silencer was added on top of stabilisers, FDA granting accelerated approval to the first BAFF/APRIL inhibitor for IgA nephropathy on a proteinuria surrogate, PRAC bringing Litfulo into line with the JAK inhibitor class warnings, PRAC confirming a small meningioma risk with prolonged desogestrel and etonogestrel use, and Vertex agreeing to buy Crinetics for about $10 billion.
This week: WHO opening enrolment in PARTNERS, the first randomised treatment trial for Bundibugyo Ebola, FDA extending Casgevy to children aged 2 and over partly by extrapolation, the European Commission approving intrathecal onasemnogene abeparvovec for older SMA patients, FDA adding a class-wide hypoglycaemia warning to JAK inhibitors for patients with diabetes, and Takeda signing an AI discovery collaboration with Insilico.
This week: HHS launching Operation TrialBlazer, FDA making one pivotal trial plus confirmatory evidence the planning default, CHMP recommending revocation of Tavneos over data integrity concerns, new safety actions for liquid rifampicin and Ixchiq, and AbbVie agreeing to buy Apogee for about $10.9 billion.
This week: FDA extending the real-time clinical trials comment period to June 29 as the final window to shape AI-integrated trial monitoring, a practical guide to what happens between an FDA 483 and a Warning Letter, EMA opening a new signal investigation into semaglutide and peripheral nerve damage, FDA concluding that any drug targeting the PRC2 protein complex carries class-wide cancer risk regardless of the specific target, and Sanofi presenting its vision for halving drug development timelines through AI on a unified data platform.
This week: Bristol Myers Squibb positioning Anthropic's Claude as its enterprise-wide intelligence layer across clinical development and regulatory submissions, FDA approving the first TROP2 antibody-drug conjugate for first-line metastatic triple-negative breast cancer, EMA's CHMP recommending the first oral GLP-1 for weight management in Europe, Japan issuing an emergency safety communication after 20 Tavneos-related deaths from liver injury, and two positive Phase 3 trials establishing inhaled treprostinil as a potential new standard of care for idiopathic pulmonary fibrosis.
This week: a new global standard that defines how clinical trial protocols should be structured and exchanged electronically for the first time, FDA's proposal to withdraw a vasculitis drug over alleged pivotal data manipulation and rising liver injury concerns, a French AI company signing a multi-year agent-building deal with AstraZeneca while others flee EU regulation, a cancer drug pulled from market after causing new blood cancers in trial patients, and Novo Nordisk deploying an AI reasoning agent for clinical data analysis on Microsoft Azure.
This week: FDA's parallel overhaul of both trial monitoring and internal review infrastructure through AI, a rare cancer drug reconsideration that tests where the evidence bar is moving, new detail on the practical fallout of OpenEvidence's EU exit, a joint FDA-industry rethink of how safety data is collected in trials, and a UK-led colorectal cancer trial reporting zero relapses at nearly three years with immunotherapy before surgery.
This week: FDA launches real-time clinical trial monitoring with AstraZeneca and Amgen, proposes withdrawing Tavneos after discovering pivotal trial data manipulation, a $12 billion clinical AI platform exits Europe over the EU AI Act, a Nature-published trial shows how to cut checkpoint combination toxicity by 60%, and Intellia reports the first positive Phase 3 for in vivo CRISPR gene editing.
This week: a wave of billion-dollar pharma-AI enterprise deals, an FDA filing acceptance that could bring the first anti-CD20 therapy for lupus, a strong CHMP month with five new medicines recommended including a first-in-class BTK inhibitor for progressive MS, a GLP-1 side-effect story generating its own clinical trials, and a cluster of positive Phase 3 late-breakers from AAN 2026.
This week: FDA's transparency crackdown on unreported trial results, new draft guidance on genome editing safety assessment, a PRAC safety action on the epilepsy drug Ontozry, post-marketing safety requirements for Lilly's obesity pill Foundayo, and two independent pancreatic cancer trials reporting doubled survival.
This week: a major proposed cut to NIH funding, FDA's broader shift toward flexible evidence standards, EMA's tailored biosimilar evidence model, a more practical read on how real-world data is actually being used in trials, and a reported Lilly-Insilico deal that keeps AI drug discovery firmly on the strategic agenda.
This week: EU guidance for emergency trial activation, FDA and EMA both streamlining biosimilar evidence requirements, a broadened Ixchiq safety profile, and a Tempus-Daiichi Sankyo AI collaboration focused on biomarker discovery.
This week: safety-data standards move further into implementation, FDA sharpens the path for non-animal testing methods, EMA links CTIS upgrades to competitiveness, PRAC updates the Ixchiq risk picture, and Tempus-Merck shows where biomarker AI is heading next.